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Abstract
Background: The outcomes of patients admitted to the intensive care unit (ICU) for acute manifestation of
small-vessel vasculitis are poorly reported. The aim of the present study was to determine the mortality rate and
prognostic factors of patients admitted to the ICU for acute small-vessel vasculitis.
Methods: This retrospective, multicenter study was conducted from January 2001 to December 2014 in 20 ICUs
in France. Patients were identified from computerized registers of each hospital using the International Classification of
Diseases, Ninth Revision (ICD-9). Inclusion criteria were (1) known or highly suspected granulomatosis with polyangiitis,
eosinophilic granulomatosis with polyangiitis, microscopic polyangiitis (respectively, ICD-9 codes M31.3, M30.1, and
M31.7), or anti–glomerular basement membrane antibody disease (ICD-9 codes N08.5X-005 or M31.0+); (2) admission
to the ICU for the management of an acute manifestation of vasculitis; and (3) administration of a cyclophosphamide
pulse in the ICU or within 48 h before admission to the ICU. The primary endpoint was assessment of mortality rate
90 days after admission to the ICU.
Results: Eighty-two patients at 20 centers were included, 94 % of whom had a recent (<6 months) diagnosis of
small-vessel vasculitis. Forty-four patients (54 %) had granulomatosis with polyangiitis. The main reasons for admission
were respiratory failure (34 %) and pulmonary-renal syndrome (33 %). Mechanical ventilation was required in 51 % of
patients, catecholamines in 31 %, and renal replacement therapy in 71 %. Overall mortality at 90 days was 18 %
and the mortality in ICU was 16 %. The main causes of death in the ICU were disease flare in 69 % and infection in
31 %. In univariable analysis, relevant factors associated with death in nonsurvivors compared with survivors were
Simplified Acute Physiology Score II (median [interquartile range] 51 [38–82] vs. 36 [27–42], p = 0.005), age (67 years
[62–74] vs. 58 years [40–68], p < 0.003), Sequential Organ Failure Assessment score on the day of cyclophosphamide
administration (11 [6–12] vs. 6 [3–7], p = 0.0004), and delayed administration of cyclophosphamide (5 days [3–14] vs.
2 days [1–5], p = 0.0053).
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Conclusions: Patients admitted to the ICU for management of acute small-vessel vasculitis benefit from early,
aggressive intensive care treatment, associated with an 18 % death rate at 90 days.
Keywords: Intensive care unit, Small-vessel vasculitis, Outcome
Background
The revised International Chapel Hill Consensus Confer-
ence Nomenclature of Vasculitides [1] characterizes vas-
culitis as a function of the size of the vessel involved.
According to this nomenclature, small-vessel vasculitides
(SVV) are a group of diseases that includes antineutro-
phil cytoplasmic antibody–associated vasculitis (AAV)
and immune complex SVV. Epidemiological data on
SVV remain scarce, although they could be considered
as orphan diseases [2]. With the development of thera-
peutic strategies that include corticosteroids, immuno-
suppressants, and (plasma exchange [PLEX]), SVV
survival rates have considerably improved, from 30 to
75 % at 5 years [3]. The leading causes of death are re-
lated mainly to a life-threatening disease at the time of
diagnosis or long-term complications of immunosup-
pressive therapies, all of which may require intensive
care unit (ICU) admission [4, 5]. To date, there are only
few studies, all retrospective, in which researchers have
reported the outcomes of patients with vasculitis admit-
ted to the ICU. The reported ICU mortality rates of the
three most recent studies ranged from 11 to 52 % [6–8].
AAV, and particularly granulomatosis with polyangiitis
(GPA; Wegener’s granulomatosis), was the most fre-
quent form of vasculitis. Unfortunately, all three were
single-center studies and heterogeneous in nature, as
they included several types of vasculitides with different
prognoses. Patients were admitted either in the initial
phase of the disease or after a long-term evolution. Fi-
nally, therapeutic vasculitis management was poorly de-
scribed and mostly inhomogeneous between studies.
Nonspecific ICU scores at admission, such as the Sim-
plified Acute Physiology Score II (SAPS II) or Sequential
Organ Failure Assessment (SOFA) score, have been re-
ported to be associated with outcome; however, specific
vasculitis scores are not adapted to the ICU setting. In
light of these circumstances, we carried out a retrospect-
ive, multicenter study to describe the clinical course,
outcomes, and prognostic factors of patients admitted to
the ICU for acute manifestation of new-onset SVV.
Methods
Study design
In this retrospective, observational, multicenter study, 22
ICUs in northern France were contacted individually by
e-mail on three occasions to analyze the outcomes of pa-
tients admitted to the ICU for acute manifestations of
SVV. Two of the centers did not partake in the study. In
the 20 participating centers, patients were identified by
two methods:
1. We used the computerized registers of each hospital
to identify patients with the International
Classification of Diseases, Ninth Revision (ICD-9),
codes M31.3 for GPA, M30.1 for eosinophilic GPA,
M31.7 for microscopic polyangiitis, and N08.5X-005
or M31.0+ for anti–glomerular basement membrane
(GBM) antibody disease.
2. If no patient was found in the computerized
database of the medical informatics department,
then the following keywords were searched in the
hospital report database of each ICU department:
“microscopic polyarteritis,” “granulomatosis with
polyangiitis (or Wegener’s),” “eosinophilic
granulomatosis with polyangiitis (or Churg-Strauss),”
“anti-glomerular basement membrane disease (or
Goodpasture syndrome).”
All patients admitted to the ICU for SVV management
were screened. When a patient was hospitalized in the
ICU on more than one occasion, only the first ICU ad-
mission was considered.
Inclusion criteria
To be included, patients had to fulfill the following criteria:
1. Patients had to be admitted to the ICU for acute
manifestations of known or highly suspected SVV
(new diagnosis or relapse). On the basis of the
results of previously published studies, acute
manifestations of known or highly suspected SVV
requiring admission in ICU include respiratory
failure, acute renal failure, cardiac failure, coma due
to central nervous system involvement, and severe
gastrointestinal involvement (e.g., peritonitis due to
small intestine perforation) [6, 9, 10].
2. Patients had to receive cyclophosphamide pulse
therapy according to French recommendations
[11, 12] within 48 h before admission or during their
ICU stay.
3. Primary SVV patients were included if they
presented with a diagnosis of AAV: microscopic
polyarteritis, GPA (formerly known as Wegener’s
granulomatosis), and eosinophilic GPA (formerly
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known as Churg–Strauss syndrome). Due to similar
clinical presentation and initial treatment in the ICU,
patients with anti–GBM antibody disease (an immune
complex vasculitis formerly known as Goodpasture
syndrome) were also included in this study.
Exclusion criteria
Considering their heterogeneous clinical presentation
and management, other immune complex SVV (cryoglo-
bulinemic vasculitis, immunoglobulin A vasculitis, hypo-
complementemic urticarial vasculitis [anti-C1q vasculitis])
were excluded from this analysis. Details on SVV not
included in the present study are provided in Additional
file 1. Patients admitted for an infectious complication
secondary to SVV immunosuppressive treatments were
excluded from the study.
Data collection
Each clinical record, in either paper or electronic form,
was reviewed at each site by the principal investigator.
All scores were calculated by the same principal investi-
gator to ensure interscore reliability. At ICU admission,
the following data were collected for each patient: demo-
graphic data; reason for admission; medical history; SVV
diagnosis type; and disease assessment scores, including
SAPS II score, SOFA score, Birmingham Vasculitis Ac-
tivity Score (BVAS) (version 3), and revised Five-Factor
Score (FFS).
SAPS II and SOFA scores were used to assess disease
severity. The SAPS II score is calculated using the worst
12 physiological variables during the first 24 h in the
ICU and also includes three disease-related variables
[13]. The SOFA score is based on six physiological vari-
ables and can be calculated on a daily basis [14].
Vasculitis disease activity was assessed on the basis of
the BVAS [15]. This score is based on clinical and bio-
logical items in nine separate organ systems: general; cu-
taneous; mucous membrane and eyes; ear, nose, and
throat; cardiovascular; gastrointestinal; pulmonary; renal;
and nervous system. The revised FFS was calculated at
admission for patients with microscopic polyangiitis,
GPA, eosinophilic granulomatosis with polyangiitis, and
anti–GBM antibody disease. This score is used to assess
prognosis at the time of diagnosis and includes the fol-
lowing items: serum creatinine level (>150 μmol or
<150 μmol); presence of severe gastrointestinal tract
involvement; cardiomyopathy; age; and ear, nose, and
throat involvement [10].
Study endpoints
The primary endpoint was assessment of mortality rate
90 days after ICU admission. Outcome was also re-
corded (survivors and nonsurvivors) in the ICU and at
day 90. For each patient, three specific adverse events
reflecting global consequences of immunosuppression
were recorded during the ICU stay: sepsis, hemorrhagic
syndrome, and hematological disorders such as aplasia
and thrombopenia. The incidence of these adverse
events was collected only if they occurred at least 48 h
after the cyclophosphamide pulse. The duration between
the cyclophosphamide pulse and each adverse event was
also recorded. Details are provided in Additional file 1.
Ethics
According to French law (L.1121-1 paragraph 1 and
R1121-2, Public Health Code), neither informed consent
nor approval of an ethics committee was necessary for
anonymous data extraction from and analysis of patients’
medical files.
Statistical analysis
Continuous variables are presented as median and inter-
quartile range, and categorical variables are reported as
frequency (percent). Two groups were defined according
to 90-day mortality: survivors and nonsurvivors. Com-
parison between the two groups was performed on con-
tinuous variables using Mann–Whitney U tests due to a
nonnormal distribution of all variables. For qualitative
variables, a χ2 test or Fisher’s exact test was used as ap-
propriate. Correlations were assessed using the Pearson
correlation test. Association between baseline ICU char-
acteristics with mortality was assessed in univariable and
multivariable logistic regression. Given the low number
of events, only two explanatory variables could be en-
tered in the multivariable models; that is, several models
were constructed, each containing two explanatory vari-
ables. These candidate variables entered in multivariable
analysis were chosen on the basis of the preceding uni-
variable analysis (entry criteria p < 0.05 in univariable
analysis). Models adjusted for various possible con-
founders (age, SOFA score at admission, SAPS II at ad-
mission) were ultimately presented. Because of the
absence of a universally accepted threshold, continuous
variables were categorized according to the thresholds
identified using the Youden index from receiver operat-
ing characteristic curve analyses. Mortality was de-
scribed using Kaplan–Meier survival estimates and
compared between the group baseline characteristics
by log-rank tests. All analyses were performed using
Prism software (GraphPad Software, La Jolla, CA, USA)
and IBM SPSS Statistics 20.0 software (IBM, Armonk,




The study population characteristics are provided in
Table 1. In the 20 participating centers, 82 patients (36
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women, 46 men) with a median age of 67.0 years (63.0–
74.5) were included from January 2001 to December 2014
(Fig. 1). The delay between traditional hospitalization
wards and ICU admission was 6.5 days (1–14). Among
the study population, 52 patients (63 %) had no prior med-
ical history and 78 patients (95 %) had a performance sta-
tus score of 0 or 1. Of the included patients, 77 (94 %)
were admitted for a new or recent diagnosis of SVV, with
GPA (Wegener’s) being the main diagnosis (44 patients,
54 %). Thirteen patients (16 %) were admitted to the ICU
for an anti-GBM antibody disease. The predominant clin-
ical patterns at admission were pulmonary-renal syndrome
(27 patients, 33 %), isolated respiratory failure (28 patients,
34 %), and isolated renal failure (24 patients, 29 %). Rea-
sons for admission for all patients with acute renal failure
were indications of renal replacement therapy with the
need to pursue PLEX. SAPS II and BVAS at admission
were 37.5 (28.0–46.5) and 16.0 (12.0–20.0), respectively.
Small-vessel vasculitis and ICU management
Data for small-vessel vasculitis and ICU management
are provided in Table 2. All patients received cyclophos-
phamide with a median dose of 1000 mg (800–1000).
Glucocorticoid pulses were administered in 74 patients
(90 %), and 79 patients (96 %) received daily high-dose
glucocorticoids. PLEX was performed in 63 patients
(77 %). In the ICU, 42 patients (51 %) required mechan-
ical ventilation during 11.5 days (8.0–22.5) and 25 pa-
tients (31 %) received vasopressor therapy during
7.0 days (3.0–18.5). Renal replacement therapy was per-
formed in 58 patients (71 %) for 13.0 days (8.0–20.75)
and was maintained after ICU stay in 28 patients (34 %).
Adverse events in the ICU
Data for adverse events in the ICU are given in Table 3.
Nine patients (11 %) presented with neutropenia <1500/
mm3 after the cyclophosphamide pulse, three (4 %) of
whom had a nadir <500/mm3. Infection was reported in
25 patients (30 %), with the lung being the most fre-
quently infected site (15 patients, 60 %), predominantly
by Gram-negative microorganisms (16 patients, 64 %).
Unfavorable evolution toward septic shock was observed
in 13 patients (16 %). Venovenous extracorporeal mem-
brane oxygenation was initiated for refractory respiratory
failure in six patients (7 %), four of whom survived.
Lastly, 57 patients (69 %) presented with at least one
hemorrhagic syndrome during their ICU stay. The main
cause of death in the ICU was disease flare in 69 % of
cases, followed by infection in 31 % of cases.
Comparison between survivors and nonsurvivors at
90 days
Data derived from comparison of survivors and nonsur-
vivors at 90 days are provided in Table 4, and the results
Table 1 Baseline demographic characteristics of 82 study patients
at admission to ICU
Characteristics Data
Age, yr 67.0 (63.0–74.5)
Female sex 36 (44)
Medical history
Malignant disease 5 (6)
Chronic renal failure 7 (8)
Heart failure 11 (13)
Chronic respiratory failure 7 (8)





0: Normal activity 37 (45)
1: Symptomatic but completely ambulatory 41 (50)
2: Less than 50 % of daytime in bed 4 (5)
3: More than 50 % of daytime in bed 0 (0)
4: Totally confined to bed or chair 0 (0)
Small-vessel vasculitis diseases
Granulomatosis with polyangiitis 44 (54)
Microscopic polyangiitis 20 (24)
Eosinophilic granulomatosis with polyangiitis 5 (6)




Newly or recently diagnosed 77 (94)
Relapsing disease 5 (6)




Respiratory failure 28 (34)
Acute renal failure 24 (29)
Pulmonary-renal failure 27 (33)
Septic shock 1 (1)
Othersc 3 (4)
Disease and severity assessment scores at admission
Simplified Acute Physiology Score II 37.5 (28.0–46.5)
Sequential Organ Failure Assessment score 5.0 (4.0–8.0)
Birmingham Vasculitis Activity Score 16.0 (12.0–20.0)
Revised Five-Factor Score 2.0 (1.0–2.0)
Data are presented as number (%) or median (interquartile range)
aMissing data: 3
bMissing data: 1
cTwo patients with encephalitis and one with myocarditis
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of univariable and multivariable analyses are given in
Table 5.
Overall mortality was 18 % (15 deaths) (Fig. 2). All pa-
tients with an anti-GBM disease survived at 90 days.
Anti-GBM disease is known to have a better prognosis,
which may have lowered the mortality rate. After remov-
ing patients with anti-GBM disease and considering only
patients with AAV, we found that the mortality rate in
the ICU and at 90 days remained less than 20 % and less
than 25 %, respectively.
Sex, medical history, performance status before ICU
admission, vasculitis type, delay between hospitalization
ward and ICU admission, reason for admission, induc-
tion treatment for SVV, revised FFS, BVAS, and SOFA
score at admission were not significantly different be-
tween survivors and nonsurvivors.
Nonsurvivors were older than survivors (67 years [62.0–
74] vs. 58.0 years [40–68], p = 0.003). SAPS II score was
also significantly higher at ICU admission in nonsurvivors
than in survivors (51 [38–82] vs. 36 [27–42], p = 0.005). A
Fig. 1 Flowchart of the included patients with outcome at 90 days, * no patient received rituximab
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higher SOFA score on the day of cyclophosphamide ad-
ministration (survivors 6 [3–7] vs. nonsurvivors 11 [6–
12], p = 0.0004), with a threshold value of 8 (sensitivity
73 %, specificity 88 %), was associated with death (Fig. 3).
A delayed administration of cyclophosphamide after ICU
admission (survivors 2.0 days [1.0–5.0] vs. nonsurvivors
5.0 days [3.0–14.0], p = 0.0053), with a threshold value of
3.5 days (sensitivity 73 %, specificity 61 %), was also associ-
ated with unfavorable evolution.
In univariable logistic regression, SOFA score on the
day of cyclophosphamide administration and timing be-
tween admission and administration of cyclophospha-
mide were significantly associated with outcome
(respectively, odds ratio [OR] with 95 % confidence
interval [CI] for a 1-point increase in SOFA score 1.32
[1.13–1.55], p < 0.001; and for a 1-day increase in delay
1.15 [1.04–1.28]; p = 0.007) (Table 5).
In multivariable analysis (Table 5), both SOFA score
on the day of cyclophosphamide administration and tim-
ing between admission and administration of cyclophos-
phamide were significantly associated with outcome (OR
for a 1-day increase in delay 1.16 [95 % CI 1.05–1.29], p
= 0.005; and OR for a 1-point increase in SOFA 1.35
[1.14–1.60]; p < 0.001). All other models identified a sig-
nificant association for delay between admission and ei-
ther administration of cyclophosphamide or SOFA score
on the day of cyclophosphamide administration, except
when adjusted for SAPS II (OR 1.20 [95 % CI 0.96–
1.48], p = 0.11).
All nonsurvivors received mechanical ventilation and
vasopressor therapy (Additional file 2: Table 6).
Discussion
The main results of the present multicenter study of pa-
tients admitted to the ICU with SVV are as follows: (1)
Table 2 Small-vessel vasculitis and intensive care management
Data (N = 82 patients)
Small-vessel vasculitis management
Number of patients receiving glucocorticoid
induction treatment
74 (90)
Number of days 3.0 (3.0–3.0)
Total dose, mg methylprednisolone
equivalents
1500 (1500–3000)
Number of patients receiving daily
glucocorticoids after induction treatment
79 (96)
Number of patients receiving plasma exchange 63 (77)
Number of sessions 7.0 (5.0–7.0)
Number of patients receiving cyclophosphamide
pulse
82 (100)
Induction dose, mg 1000 (800–1000)
Number of patients receiving rituximab 3 (4)
ICU management
Number of patients receiving mechanical
ventilationa
42 (51)
Duration of mechanical ventilation, days 11.5 (8.0–22.5)
Number of patients receiving venovenous
extracorporeal membrane oxygenation
6 (7)
Number of patients receiving catecholamines 25 (31)
Duration of catecholamine administration,
days
7.0 (3.0–18.5)
Number of patients receiving renal replacement
therapy in ICU
58 (71)
Duration of renal replacement therapy in ICU,
days
13.0 (8.0–20.75)
Number of patients receiving renal
replacement therapy before ICU stay
11 (13)
Number of patients receiving renal
replacement therapy after ICU stay
28 (34)
ICU intensive care unit
Data are presented as number (%) or median (interquartile range)
aIncluding invasive and noninvasive ventilation
Table 3 Summary of prespecified adverse events recorded in
the ICU
Data (N = 82 patients)
Neutropeniaa <1500/mm3 9 (11)
Delay between cyclophosphamide
administration and neutropeniaa <500/mm3,
days
16 (2–25)
Number of patients with infection 25 (30)
Location








No pathogen identified 5 (20)
Delay between ICU admission and first
infection event, days
13.0 (4.5–19.75)
Number of patients with septic shock 13 (16)
Number of patients presenting with
hemorrhagic syndrome
57 (69)
Number of packed red blood cells infused
during ICU stay
4.0 (0–7.5)
Delay between ICU admission and first
hemorrhagic event, days
1.0 (0–5.0)
Cause of death in ICU
Infection 4 (31)
Disease flare 9 (69)
ICU intensive care unit
Data are presented as number (%) or median (interquartile range)
aMissing data: 2
bVirus
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mortality represented about one-fifth of the included
population, despite life-threatening manifestations at ad-
mission requiring aggressive immunosuppressive ther-
apy; (2) subject to other undetected confounding factors
that we were not able to include in the multivariable
analysis, ICU severity score, such as SOFA score on the
day of cyclophosphamide administration in the ICU, also
seemed to be associated with unfavorable outcome; and
(3) delayed administration of cyclophosphamide was also
likely associated with death.
Causes of ICU admission
Due to the noninclusion criteria, only one patient pre-
sented with septic shock at admission and was diagnosed
thereafter with AAV. Consequently, all patients were ad-
mitted for acute manifestations of the disease, which
Table 4 Comparison of survivors and nonsurvivors at 90 days
Survivors (n = 67) Nonsurvivors (n = 15) p Value
Age, yr 58.0 (40.0–68.0) 67.0 (62.0–74.0) 0.003
Female sex 30 (44) 6 (40) 0.78
Medical history
Malignant disease 3 (4) 2 (13) 0.055
Chronic renal failure 6 (9) 1 (6)
Chronic respiratory failure 5 (7) 2 (13)
Heart failure 6 (9) 5 (33)
Neurological failure 1 (1) 0 (0)
Diabetes 3 (4) 2 (13)
Malnutrition 1 (1) 1 (6)
None 46 (68) 6 (40)
Performance statusa 2.0 (1.0–2.0) 2.0 (1.0–2.0) 0.68
Small-vessel vasculitis diseases
Granulomatosis with polyangiitis 37 (55) 7 (47) 0.06
Microscopic polyangiitis 13 (20) 7 (47)
Eosinophilic granulomatosis with polyangiitis 4 (5) 1 (6)
Anti–glomerular basement membrane antibody disease 13 (20) 0 (0)
Delay between hospitalization ward to admission to ICU, days 5.0 (1.0–12.0) 11.0 (2.0–28.0) 0.21
Reason for admission
Respiratory failure 1 (29) 8 (54) 0.37
Acute renal failure 22 (32) 2 (13)
Pulmonary-renal failure 22 (32) 5 (33)
Septic shock 1 (2) 0 (0)
Othersb 3 (5) 0 (0)
Number of patients receiving glucocorticoid induction treatment 62 (92) 12 (80) 0.15
Number of patients receiving plasma exchange 50 (75) 13 (86) 0.50
Disease and severity assessment scores at admission
Revised Five-Factor Score 2.0 (1.0–2.0) 2.0 (1.0–3.0) 0.88
Simplified Acute Physiology Score II 36 (27–42) 51.0 (38.0–82.0) 0.005
Sequential Organ Failure Assessment score at admission 4.0 (4.0–7.0) 8.0 (6.0–9.0) 0.008
Birmingham Vasculitis Activity Score 16.0 (12.0–20.0) 16.0 (12.0–20.0) 0.85
Sequential Organ Failure Assessment score at cyclophosphamide administration 6.0 (3.0–7.0) 11.0 (6.0–12.0) 0.0004
Delay between ICU admission and cyclophosphamide administration, days 2.0 (1.0–5.0) 5.0 (3.0–14.0) 0.0053
ICU intensive care unit
Data are presented as number (%) or median (interquartile range)
aMissing data: 3
bTwo patients with encephalitis and one with myocarditis
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consisted mainly of acute respiratory failure or/and acute
renal failure. Overall, respiratory failure was present in
two-thirds of our patients. In accordance with this, in
the studies of Khan et al. [7] and Monti et al. [16], clin-
ical presentations such as acute respiratory failure re-
lated to diffuse intraalveolar hemorrhage were also
reported to be the first manifestation of AAV at ICU
admission.
Immunosuppressive therapy–related infection in the ICU
The rate of acquired infection hovered at 30 % and was
surprisingly less than that of other populations usually
admitted to the ICU [17]. This low rate of infection may
be explained by the low exposure of patients to chronic
immunosuppressive therapies: Only four patients had
been receiving chronic immunosuppressive therapy for
more than 6 months before ICU admission. In a retro-
spective series, Cruz et al. found that patients admitted for
an infectious process tended to have a higher mortality
rate [9]. Similarly, Befort et al. recently reported that cause
of death was related mainly to an infectious process in
61 % of ICU patients [6]. Prolonged exposure to immuno-
suppressive therapies such as corticosteroids before ICU
admission is also known to be independently associated
with a higher risk of death [18]. Conversely, results from
the CORTAGE trial confirmed that low cumulative doses
of corticosteroids and limited doses of cyclophosphamide
at 500 mg per pulse were associated with a lower occur-
rence of infection in the elderly [19].
Cyclophosphamide has long been the standard induc-
tion treatment in acute manifestations of severe AAV.
Randomized controlled trials have also shown that ritux-
imab was noninferior to cyclophosphamide therapy for
remission induction in these patients [20, 21]. However,
the latter study excluded patients with either alveolar
hemorrhage sufficiently severe to require mechanical
ventilation or with a serum creatinine level greater than
350 μmol/L. Patient subset analyses including one-
fourth of participants with diffuse alveolar hemorrhage
or those with major renal disease did not reveal any
between-arm differences in remission rate [21]. In these
studies, there were no significant differences between
the two treatments with respect to adverse events. In the
particular setting of the ICU, one can speculate whether
rituximab would not be safer than cyclophosphamide for
infectious adverse events [22].
It is noteworthy that a high number of our patients
were treated with PLEX as an adjunct for frequent acute
respiratory failure and/or acute renal failure at patient
admission. Patients with respiratory failure due to diffuse
alveolar hemorrhage are thought to benefit from PLEX,
and the rate of renal recovery in AAV presenting with
renal failure has furthermore been shown to be in-
creased with PLEX [23]. The latter is the subject of a
large, ongoing, multicenter randomized controlled trial
to confirm these data in this patient population (PEXI-
VAS; ClinicalTrials.gov identifier NCT00987389).
Table 5 Results of uni- and multivariable analysis
Association between delay from ICU
admission to cyclophosphamide
administration and outcome
Association between SOFA score at
cyclophosphamide administration
and outcome
Model OR (CI) p OR (CI) p
Univariable model 1.15 (1.04–1.28) 0.007 1.32 (1.13–1.55) <0.001
Multivariable models
Adjusted for age 1.14 (1.03–1.27) 0.01 1.33 (1.12–1.58) 0.001
Adjusted for SOFA score at admission 1.16 (1.04–1.28) 0.008 1.35 (1.11–1.64) 0.003
Adjusted for SAPS II at admission 1.16 (1.04–1.29) 0.01 1.20 (0.96–1.48) 0.11
Adjusted for SOFA score at cyclophosphamide administration 1.16 (1.05–1.29) 0.005 – –
Adjusted for delay between ICU admission and cyclophosphamide
administration
– – 1.35 (1.14–1.60) <0.001
CI confidence interval, ICU intensive care unit, OR odds ratio, SAPS Simplified Acute Physiology Score, SOFA Sequential Organ Failure Assessment
Data are presented as odds ratio (95 % confidence interval)
Fig. 2 Kaplan–Meyer curves estimating the rate of survival at
90 days. The dashed line represents the 95 % confidence interval.
Values below each time point indicate the number of
surviving patients
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Prognostic factors
Despite increased use, intensivists do not routinely pre-
scribe immunosuppressive therapies for the management
of severe vasculitis. In the ICU, their prescription in in-
stances of multiple organ failure could seem counterin-
tuitive at first glance and most often is associated with
an increased complication rate and potentially with a
negative outcome. In view of our results, this paradigm
appears not to be justified for acute manifestations of
SVV. Previous studies have furthermore found highly
heterogeneous results with regard to ICU mortality (11–
52 %). One major reason may be related to the hetero-
geneity of the included population. Indeed, most of these
studies involved, on one hand, mixed samples including
relapse and new diagnoses of various classes of necrotiz-
ing vasculitis and, on the other hand, acute manifestations
of the disease as well as chronic immunosuppressive-
related infections [6, 7, 9, 18, 24]. Owing to the high
degree of homogeneity of our population, only a small
number of factors appeared to be associated with ICU
mortality. As expected, a high SAPS II score, which is a
nonspecific ICU severity score assessed at admission, was
associated with worst outcome. This score was also sys-
tematically found to be predictive of ICU mortality in all
other previous studies [6, 7, 9, 18, 25]. In univariable and
multivariable analysis, SOFA score measured on the day
of cyclophosphamide administration in the ICU was
strongly associated with a poorer outcome. The delayed
administration of cyclophosphamide in the ICU was also
associated with a higher mortality rate. Considering that
all patients included in this study presented with an acute
manifestation of SVV, it is not surprising that delayed ad-
ministration of the induction immunosuppressive treat-
ment was associated with death. Similar to the results of
the studies of Cruz et al. [9] and Khan et al. [7], BVAS was
also a poor predictor of ICU mortality. Indeed, a number
of items in this score are a reflection much more of vascu-
litis activity than of an acute life-threatening manifestation
of SVV. Similarly, it was not surprising that FFS was not
associated with poor outcome. In the present series, as in
others, cardiac symptoms or gastrointestinal involvement,
two main criteria included in the FFS, were rare or not
found at ICU admission [9].
Study limitations
The present study is limited by its retrospective nature.
Considering the very low incidence rate of SVV with the
prespecified inclusion criteria, it would be difficult to
conduct a prospective study. Nonetheless, we report a
large retrospective analysis of 82 patients at 20 different
centers, hence limiting center bias.
Due to the limited number of events recorded in our
moderate sample size, we could not adjust for other nu-
merous potential confounders in the multivariable
analysis. Adjusting for confounders not identified as sig-
nificant in this analysis could have weakened the associ-
ation measured.
It is usual to report the outcome of small-vessel vascu-
litis at 12 and 60 months because the efficacy of the im-
munosuppressive therapies can be assessed only after
prolonged follow-up. In the present study, we decided to
report the outcome only at 90 days for the following rea-
sons. First, the outcome at 90 days represents the
specific consequences of ICU stay. Second, with a retro-
spective multicenter study design, data for longer-term
outcomes are most often not fully available.
Conclusions
Patients admitted to the ICU for life-threatening compli-
cations at the initial phase of SVV have an 82 % survival
rate. Mortality is positively related to the intensity of
organ failure. Delayed immunosuppressant use in the
ICU appears to be associated with mortality. Thus,
the present study sheds new light on the potential
importance of a rapid approach in the treatment of
these conditions.
Fig. 3 Kaplan–Meyer curves estimating the rate of survival for a Sequential Organ Failure Assessment (SOFA) score >8 on the day of cyclophosphamide
administration (left panel) and for a delay in cyclophosphamide administration >3.5 days (right panel). Values below each time point indicate the
number of surviving patients
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Key messages
 Patients admitted to the ICU for acute manifestation
of small-vessel vasculitis have an 82 % survival rate.
 Even in the case of multiple organ failure, delayed
administration of immunosuppressants is associated
with death.
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